[go: up one dir, main page]

PL411561A1 - MicroRNA profile combined with the profile of blood protein markers as the test for detecting the lung cancer - Google Patents

MicroRNA profile combined with the profile of blood protein markers as the test for detecting the lung cancer

Info

Publication number
PL411561A1
PL411561A1 PL411561A PL41156115A PL411561A1 PL 411561 A1 PL411561 A1 PL 411561A1 PL 411561 A PL411561 A PL 411561A PL 41156115 A PL41156115 A PL 41156115A PL 411561 A1 PL411561 A1 PL 411561A1
Authority
PL
Poland
Prior art keywords
lung cancer
level
profile
mirna
expression
Prior art date
Application number
PL411561A
Other languages
Polish (pl)
Inventor
Rafał Dziadziuszko
Witold Rzyman
Ewa Szutowicz-Zielińska
Jacek Jassem
Joanna Polańska
Piotr Widłak
Original Assignee
Gdański Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny filed Critical Gdański Uniwersytet Medyczny
Priority to PL411561A priority Critical patent/PL411561A1/en
Priority to PCT/PL2016/000028 priority patent/WO2016148593A1/en
Publication of PL411561A1 publication Critical patent/PL411561A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem wynalazku jest metoda predykcyjna do wykrywania i/lub wykluczenia raka płuca, polegająca na pomiarze poziomu ekspresji miRNA i stężenia białek w próbce badanej, obejmująca: - badanie w biologicznej próbce krwi 23 miRNA oraz 6 markerów białkowych, - oznaczenie poziomu ekspresji wskazanych miRNA i stężenia wskazanych białek we krwi, względem poziomu ekspresji wskazanych miRNA, poprzez wyliczenie różnicy pomiędzy poziomem referencyjnym miRNA a zmierzoną wartością ekspresji każdego ze wskazanych miRNA, - oznaczenie i odniesienie stężenia białek do wartości referencyjnej podanej jako wartość górnego poziomu wartości referencyjnych dla danego markera białkowego w populacji osób zdrowych, do którego odnoszone jest jego stężenie w surowicy osoby badanej. Ujawniono również zestaw testowy oraz zastosowanie tej metody do wykrywania raka płuca u osób z grupy wysokiego ryzyka zachorowania na raka płuca.The subject of the invention is a predictive method for detection and / or exclusion of lung cancer, consisting in measuring the level of miRNA expression and protein concentration in a test sample, including: - testing of 23 miRNA in a biological blood sample and 6 protein markers, - determination of the level of expression of indicated miRNA and concentration indicated blood proteins, relative to the expression level of indicated miRNAs, by calculating the difference between the miRNA reference level and the measured expression value of each of the indicated miRNAs, - determination and reference of protein concentration to the reference value given as the value of the upper reference level for a given protein marker in a population of people healthy, to which its concentration in the tested person's serum is related. Also disclosed is a test kit and use of this method to detect lung cancer in individuals at high risk of developing lung cancer.

PL411561A 2015-03-13 2015-03-13 MicroRNA profile combined with the profile of blood protein markers as the test for detecting the lung cancer PL411561A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL411561A PL411561A1 (en) 2015-03-13 2015-03-13 MicroRNA profile combined with the profile of blood protein markers as the test for detecting the lung cancer
PCT/PL2016/000028 WO2016148593A1 (en) 2015-03-13 2016-03-11 A microrna profile combined with a profile of blood protein markers as a test for the detection of lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411561A PL411561A1 (en) 2015-03-13 2015-03-13 MicroRNA profile combined with the profile of blood protein markers as the test for detecting the lung cancer

Publications (1)

Publication Number Publication Date
PL411561A1 true PL411561A1 (en) 2016-09-26

Family

ID=55795158

Family Applications (1)

Application Number Title Priority Date Filing Date
PL411561A PL411561A1 (en) 2015-03-13 2015-03-13 MicroRNA profile combined with the profile of blood protein markers as the test for detecting the lung cancer

Country Status (2)

Country Link
PL (1) PL411561A1 (en)
WO (1) WO2016148593A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109628597A (en) * 2019-01-22 2019-04-16 武汉科技大学 A kind of primer, kit and the detection method of CRP and miR-365-3p joint-detection gastric cancer
WO2024128987A2 (en) * 2022-12-15 2024-06-20 MiRXES Lab Pte. Ltd. Circulating biomarkers for the detection of lung cancer and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10815517B2 (en) * 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
EP2336353A1 (en) 2009-12-17 2011-06-22 febit holding GmbH miRNA fingerprints in the diagnosis of diseases
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
EP2505663A1 (en) 2011-03-30 2012-10-03 IFOM Fondazione Istituto Firc di Oncologia Molecolare A method to identify asymptomatic high-risk individuals with early stage lung cancer by means of detecting miRNAs in biologic fluids
AU2012220872A1 (en) * 2011-02-22 2013-09-12 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers

Also Published As

Publication number Publication date
WO2016148593A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
RU2016134839A (en) BIOMARKER AND METHODS FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE
BR112014006741A2 (en) method for monitoring, diagnosis and / or prognosis of early acute kidney injury
AR103935A1 (en) METHODS OF DETECTION AND QUANTIFICATION OF IL-13 AND ITS USES IN THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH TH-2
JOP20200216A1 (en) Assays to detect neurodegeneration
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
BR112016004320A2 (en) biosensor, system, kit, methods for determining or identifying and quantifying an ammonia or ammonium ion concentration, diagnosing a metabolic disease in a subject, determining a patient's response to therapy, making a biosensor, of a system or any test strip and detecting the presence, absence, or amount of amino acids in a sample, and test strip
MX2016013255A (en) Methods and compositions for detecting misfolded proteins.
BR112014026997A2 (en) improved analyte measurement technique and system
BR112016007037A2 (en) method for detecting pancreatic cancer, monoclonal antibody and kit
BR112014029233A8 (en) method for diagnosing whether a pregnant individual is not at risk, use of at least one of the sfit-1, endoglina and pigf biomarkers, device, kit, individual management method, system and method for establishing an aid
CY1119797T1 (en) LACTOPHERINE FOR USE IN ALZHEIMER DIAGNOSIS AND PREDICTION
EA201700123A1 (en) METHOD FOR PREDICTING A VARIANT OF A MEDICAL PREPARATION FOR THE TREATMENT OF DEPRESSION
WO2015014794A8 (en) Use of alpha-crystallin b (cryab) in the assessment of heart failure
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
BR112016017901A2 (en) groundbreaking assay to detect human periostin
DE602007006671D1 (en) USE OF NNMT AS A MARKER FOR LUNG CANCER
PL411561A1 (en) MicroRNA profile combined with the profile of blood protein markers as the test for detecting the lung cancer
TW201621318A (en) Skin viscoelasticity marker and utilization of the same
MX2016012278A (en) Early detection of preeclampsia.
PL406989A1 (en) Profile of micro RNA in blood as the test for detecting lung cancer
PL406987A1 (en) Profile of blood protein markers as the test for detecting lung cancer
GB2569932A (en) Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
DE602005013430D1 (en) USING ASC AS A MARKER FOR COLORECTAL CARCINOMAS
PL422387A1 (en) Method for determination of tissue sensitivity to insulin, method for identification of insulin resistance and/or determination of predisposition to a disorder related to it, application of the insulin sensitivity index and the diagnostic kits, and their application
PL410454A1 (en) Method for identification of response of a patient with psoriasis disease to treatment with genistein, molecular test and application of gene expressions for the in vitro detection of psoriasis